Luxor Capital Group LP Purchases New Holdings in Harrow, Inc. $HROW

Luxor Capital Group LP purchased a new position in shares of Harrow, Inc. (NASDAQ:HROW) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 307,337 shares of the company’s stock, valued at approximately $14,807,000. Harrow makes up 0.7% of Luxor Capital Group LP’s holdings, making the stock its 20th biggest holding.

A number of other hedge funds have also recently added to or reduced their stakes in HROW. Royal Bank of Canada lifted its position in shares of Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after acquiring an additional 4,967 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after purchasing an additional 790 shares in the last quarter. Strs Ohio bought a new position in shares of Harrow in the first quarter worth $149,000. Geode Capital Management LLC raised its stake in Harrow by 4.7% in the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock valued at $24,765,000 after purchasing an additional 36,724 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in Harrow by 16.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 7,273 shares of the company’s stock valued at $222,000 after purchasing an additional 1,041 shares in the last quarter. Institutional investors own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

HROW has been the topic of a number of analyst reports. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 3rd. Cantor Fitzgerald dropped their target price on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. HC Wainwright lifted their price objective on shares of Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, William Blair restated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Harrow has a consensus rating of “Moderate Buy” and an average price target of $71.14.

Harrow Stock Up 2.4%

Shares of NASDAQ HROW opened at $34.91 on Tuesday. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -205.34 and a beta of 0.05. The company has a current ratio of 2.20, a quick ratio of 2.06 and a debt-to-equity ratio of 4.67. Harrow, Inc. has a 12 month low of $20.85 and a 12 month high of $54.85. The stock has a 50-day moving average price of $45.83 and a two-hundred day moving average price of $43.64.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.